Recently, LWBP released the results of a clinical phase II study of LW402, a self-developed next-generation oral JAK1 selective inhibitor, in rheumatoid arthritis (RA). The results of the clinical study showed that LW402 tablets could rapidly improve inflammation-related efficacy of the subjects, and there was a statistically significant reduction in the mean CRP value after one week of administration compared to the baseline. After 12 weeks of administration, the treatment groups showed excellent ability to improve DAS28-CRP (the primary clinical endpoint). In addition, there was no statistically significant difference in the incidence of adverse events between the treatment groups and control group, implying that LW402 has an excellent safety profile and has great potential for long-term use in autoimmune diseases.